Akash Tewari
Stock Analyst at Jefferies
(3.19)
# 1,176
Out of 4,496 analysts
46
Total ratings
48.48%
Success rate
2.73%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $47.82 | +56.84% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $994 → $1,015 | $857.47 | +18.37% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $24.83 | +101.37% | 2 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $47.50 | +57.89% | 4 | Mar 6, 2024 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $68 → $80 | $37.98 | +110.64% | 1 | Feb 5, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $31 | $29.50 | +5.08% | 1 | Dec 11, 2023 | |
| ARVN Arvinas | Upgrades: Buy | $32 → $40 | $28.52 | +40.25% | 2 | Dec 6, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $935 → $937 | $1,063.60 | -11.90% | 4 | Nov 28, 2023 | |
| SLRN Acelyrin | Maintains: Buy | $15 → $12 | $6.51 | +84.33% | 2 | Nov 28, 2023 | |
| PFE Pfizer | Upgrades: Buy | $38 → $39 | $29.97 | +30.13% | 2 | Oct 16, 2023 | |
| ENTA Enanta Pharmaceuticals | Downgrades: Hold | $49 → $18 | $14.32 | +25.70% | 2 | Aug 8, 2023 | |
| ARGX argenx SE | Maintains: Buy | $497 → $513 | $471.32 | +8.84% | 2 | Jul 17, 2023 | |
| TERN Terns Pharmaceuticals | Initiates: Buy | $18 | $8.49 | +112.14% | 1 | Jun 7, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Hold | $16 → $13 | $8.60 | +45.35% | 2 | Apr 20, 2023 | |
| MRK Merck & Co. | Initiates: Buy | $125 | $125.77 | -0.61% | 1 | Mar 6, 2023 | |
| BMY Bristol-Myers Squibb Company | Initiates: Hold | $62 | $42.64 | +45.40% | 1 | Mar 6, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $7.7 → $11 | $9.78 | +12.47% | 1 | Dec 20, 2022 | |
| THRD Third Harmonic Bio | Downgrades: Hold | $30 → $3.6 | $11.81 | -69.52% | 2 | Dec 16, 2022 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $17 | $7.33 | +131.92% | 1 | Dec 12, 2022 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $100 → $120 | $84.09 | +42.70% | 1 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Assumes: Buy | $112 | $145.69 | -23.12% | 1 | Jun 6, 2022 | |
| CYTK Cytokinetics | Initiates: Buy | n/a | $56.41 | - | 2 | Oct 7, 2021 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | n/a | $287.24 | - | 1 | Oct 7, 2021 | |
| EXEL Exelixis | Initiates: Buy | n/a | $22.60 | - | 2 | Oct 7, 2021 | |
| BNTX BioNTech SE | Initiates: Hold | n/a | $85.46 | - | 1 | Oct 7, 2021 |
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $47.82
Upside: +56.84%
Eli Lilly
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $857.47
Upside: +18.37%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $24.83
Upside: +101.37%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $47.50
Upside: +57.89%
Apellis Pharmaceuticals
Feb 5, 2024
Upgrades: Buy
Price Target: $68 → $80
Current: $37.98
Upside: +110.64%
Spyre Therapeutics
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $29.50
Upside: +5.08%
Arvinas
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $28.52
Upside: +40.25%
Regeneron Pharmaceuticals
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $1,063.60
Upside: -11.90%
Acelyrin
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $6.51
Upside: +84.33%
Pfizer
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $29.97
Upside: +30.13%
Enanta Pharmaceuticals
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $14.32
Upside: +25.70%
argenx SE
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $471.32
Upside: +8.84%
Terns Pharmaceuticals
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $8.49
Upside: +112.14%
Relay Therapeutics
Apr 20, 2023
Upgrades: Hold
Price Target: $16 → $13
Current: $8.60
Upside: +45.35%
Merck & Co.
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $125.77
Upside: -0.61%
Bristol-Myers Squibb Company
Mar 6, 2023
Initiates: Hold
Price Target: $62
Current: $42.64
Upside: +45.40%
Zymeworks
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $9.78
Upside: +12.47%
Third Harmonic Bio
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $11.81
Upside: -69.52%
Acrivon Therapeutics
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $7.33
Upside: +131.92%
BioMarin Pharmaceutical
Nov 29, 2022
Maintains: Buy
Price Target: $100 → $120
Current: $84.09
Upside: +42.70%
Neurocrine Biosciences
Jun 6, 2022
Assumes: Buy
Price Target: $112
Current: $145.69
Upside: -23.12%
Cytokinetics
Oct 7, 2021
Initiates: Buy
Price Target: n/a
Current: $56.41
Upside: -
Madrigal Pharmaceuticals
Oct 7, 2021
Initiates: Buy
Price Target: n/a
Current: $287.24
Upside: -
Exelixis
Oct 7, 2021
Initiates: Buy
Price Target: n/a
Current: $22.60
Upside: -
BioNTech SE
Oct 7, 2021
Initiates: Hold
Price Target: n/a
Current: $85.46
Upside: -